西澳大利亚非小细胞肺癌PD-L1表达与临床病理特征的相关性
该研究分析了西澳大利亚241例非小细胞肺癌标本的PD-L1免疫组化表达(22C3克隆,Dako平台),按肿瘤比例评分(TPS)1%、1-49%、≥50%分组。结果显示鳞状细胞癌PD-L1阳性率92%,腺癌67%;TPS≥50%在鳞癌中更高(p=0.004),腺癌中更低(p=0.003);PD-L1表达与分子遗传学异常、年龄、性别、分期及吸烟状态无显著相关。
要点
- 鳞状细胞癌PD-L1阳性率92%,腺癌67%,鳞癌TPS显著更高(p=0.004)。
- TPS≥50%总体患病率与临床试验报道一致。
- PD-L1表达与RAS/EGFR/ALK/ROS1异常及临床参数无显著相关。
核心结论
- 鳞状细胞癌PD-L1 TPS显著高于腺癌(p=0.004),腺癌TPS显著更低(p=0.003)。
- PD-L1表达与分子遗传学异常及年龄、性别、分期、吸烟状态无显著相关。
研究设计与样本
- 回顾性分析西澳大利亚主要公立医院241例非小细胞肺癌标本。
- 采用22C3克隆在Dako自动染色平台行PD-L1免疫组化,按TPS 1%、1-49%、≥50%分组。
主要发现
- TPS 1%者65例(27%),1-49%者100例(41%),≥50%者76例(32%)。
- 鳞状细胞癌PD-L1阳性率92%,腺癌67%。
- 196例非鳞癌中,RAS突变35%,EGFR突变13%,ALK易位2%,ROS1易位2%。
- TPS≥50%见于34%(23/68)RAS突变、28%(7/25)EGFR突变、25%(1/4)ALK易位癌。
关键数值与推荐
- TPS分组阈值为1%、1-49%、≥50%。
- 鳞状细胞癌TPS较高(p=0.004),腺癌较低(p=0.003)。
临床怎么用
- PD-L1 TPS可用于非小细胞肺癌免疫检查点抑制剂治疗的预测评估。
- 鳞癌与腺癌PD-L1表达分布不同,解读时应结合组织学类型。
局限性
- 原文未明确报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immune checkpoint inhibition is an important therapeutic option in patients with non-small cell lung cancer. Programmed cell death ligand-1 (PD-L1) expression may serve as a predictive marker for anti-PD-1/PD-L1 therapies. The relationship between non-small cell lung cancer PD-L1 expression and clinicopathological characteristics remains unclear and there is no population level Australian data. We report the results of PD-L1 testing in patients with non-small cell lung cancer diagnosed at major Western Australian public hospitals served by a single state Pathology provider. We analyzed PD-L1 expression by immunohistochemistry in 241 non-small cell lung cancer specimens using the 22C3 clone on a Dako autostainer platform. Tumor cell PD-L1 expression was scored as Tumor Proportion Score and categorized using pre-specified subsets of 1%, 1-49% and ≥ 50% for correlation with clinicopathologic features. PD-L1 Tumor Proportion Score was 1% in 65 (27%) cases, 1-49% in 100 (41%) cases and ≥ 50% in 76 (32%) cases. PD-L1-positive rate was 92% in squamous cell carcinomas and 67% in adenocarcinomas. PD-L1 Tumor Proportion Score was higher in squamous cell carcinomas (p = 0.004) and lower in adenocarcinomas (p = 0.003). Of the 196 non-squamous carcinomas, 35% had rat sarcoma viral oncogene homolog (RAS) mutations, 13% had epidermal growth factor receptor (EGFR) mutations, 2% had anaplastic lymphoma kinase (ALK) translocations and 2% had ROS1 translocations. Tumor Proportion Score ≥ 50% was seen in 34% (23/68), 28% (7/25) and 25% (1/4) of RAS, EGFR mutant, and ALK translocated carcinomas, respectively. There was no significant correlation between PD-L1 expression and molecular or genetic abnormalities, or other parameters including age, gender, stage, and smoking status. In our patient cohort, PD-L1 Tumor Proportion Score was significantly higher in squamous cell carcinomas and lower in adenocarcinomas. The overall prevalence of Tumor Proportion Score ≥ 50% is consistent with that reported in clinical trials.
引用
- Ye L, Leslie C, Jacques A, et al. Programmed death ligand-1 expression in non-small cell lung cancer in a Western Australian population and correlation with clinicopathologic features. Mod Pathol. 2018. PMID: 30401947. doi:10.1038/s41379-018-0173-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。